Navigation Links
Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
Date:10/21/2007

PARIS, Oct. 21 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for a Supplemental New Drug Application (sNDA) for the indication of "Acute coronary syndrome (unstable angina pectoris, non-ST elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is being planned" for Plavix(R) (clopidogrel).

Approximately 100,000 patients develop an acute coronary syndrome (ACS) and elect to undergo PCI every year in Japan -- where Plavix(R) is now the first drug approved in this indication --, the largest number of patients in the world outside of the United States. "We are pleased that the innovative therapy, Plavix(R) is now available to physicians in Japan, offering them a new treatment option with proven outcomes and safety across ACS patients with planned PCI," said Hanspeter Spek, Executive Vice-President Pharmaceutical Operation of sanofi-aventis.

In Japan, this new cardiology (ASC) extension completes the recent approval (May 2006) in the reduction of recurrence of stroke for which the 2 weeks-prescription-only-limitation has been lifted in May 2007, as result of the favorable one year safety assessment.

The efficacy and safety profile of Plavix(R) is well established in multiple large-scale Japanese and international landmark clinical trials involving more than 100,000 patients as well as from real-life clinical experience in more than 70 millions patients worldwide including Japan.

Japanese guidelines(1, 2) suggest that Plavix(R) can fill an important medical need for patients with UA-NSTEMI. Outside Japan, Plavix(R) is also recommended in multiple national and international guidelines (US [ACC/AHA] and European [ESC]) (3,4,5,6,7,8) for ACS, heart attack, recent MI, stroke and/or P.A.D patients at risk for future atherothrombotic events as a standard treatment for millions of patients at cardiovascular risk.

Outside
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
2. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... preclinical animal research imaging system market ... multimodality imaging, such as combining computed tomography and ... imaging. This demand stems from the need for ... among scientific journals, which will spur preclinical imaging ...
(Date:7/30/2014)... WESTFORD, Mass. , July 30, 2014 ... in laser- and light-based aesthetic treatments for non-invasive and minimally ... promoted Executive Vice President, Chief Operating Officer and Chief Financial ... Company, effective August 1, 2014.  Baker, 53, will continue to ... from Michael Davin , who remains Chairman and Chief ...
(Date:7/30/2014)... PHILADELPHIA , July 30, 2014  Packaging Coordinators, ... a definitive agreement to acquire Penn Pharmaceutical Services Limited ... Wales in the United Kingdom ... New Hope, Pennsylvania and Tokyo ... manufacturing services, including Clinical and Commercial dosage form manufacturing, ...
Breaking Medicine Technology:Growing Popularity of Multimodality Imaging Will Drive the Preclinical Animal Research Imaging System Market 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... AVENTURA, Fla., Aug. 15, 2011 Double Eagle ... has retained National Securities Corporation as the ... round of capitalization, as well as possible acquisition and ... company of Fuse Science, Inc. ( www.fusescience.com ), the ...
... MINNETONKA, Minn., Aug. 15, 2011 Uroplasty, Inc. (Nasdaq: ... develops, manufactures and markets innovative proprietary products to treat ... clinical studies using Uroplasty,s Urgent® PC Neuromodulation System are ... meeting, August 29-September 2, 2011 in Glasgow, Scotland.   ...
Cached Medicine Technology:Double Eagle Holdings Chooses National Securities Corporation as Exclusive Investment Banker 2Urgent® PC Clinical Studies Results Scheduled for Presentation at International Continence Society 2Urgent® PC Clinical Studies Results Scheduled for Presentation at International Continence Society 3
(Date:7/31/2014)... Parsippany, NJ (PRWEB) July 31, 2014 A ... millions of people survive cancer and resume normal lives. This ... American Cancer Society, will affect one in seven American men ... are, has a five-year survival rate of nearly 100% and ... serious illness but most men diagnosed with the disease do ...
(Date:7/31/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... at 11 drug addiction facts that children aren’t taught in ... some kids learn a little about the dangers of alcohol ... woefully inadequate,” commented Best Drug Rehabilitation’s Per Wickstrom . ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Continuing ... the upcoming inaugural Clinical Issues in Primary Care ... October 13-17, 2014 at the Wailea Beach Marriott Resort ... agenda has been developed for today's Primary Care ... critical CME topics," says Barbara Lyons, VP Education. , ...
(Date:7/31/2014)... 31, 2014 Nuanced Media, a leading ... of the Nuanced Medical website . Nuanced Medical, ... needs of the Medical Industry. , The idea behind ... for medical practices to meet continuously changing federal regulations. ... HIPAA Act (Health Insurance Portability and Accountability Act), which ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The ... with the Penn's Abramson Cancer Center, will host a ... together area experts in the field of mesothelioma. September ... The conference is open to the public, and specifically ... and those who have been exposed to asbestos. , ...
Breaking Medicine News(10 mins):Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 2Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 3Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 4Health News:New Best Drug Rehabilitation Blog Posts Looks at 11 Drug Addiction Facts they Don’t Teach in School 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3Health News:Nuanced Media, HIPAA Certified Agency, Launches Medical Web Design Service Website 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3
... study in the Sept.1 issue of the journal ... workplace bullying is associated with increased sleep disturbances. Associations ... indicating that bullying has detrimental effects even when it ... high prevalence of workplace bullying, with 11 percent of ...
... More than 1,000 Reported Incidents, Caregivers Call for Comprehensive Process to ... Aug. 31 Home care workers called for a hand-examination ... the workers, union, saying they had been subjected to lies, coercion, ... members of the Service Employees International Union, United Healthcare Workers - ...
... Insurance company ... flight , ... August 31, 2009 -- Last year, Sally (a patient suffering from end stage liver failure) ... transplant. Her doctors told her she needed to receive the evaluation in order to get ...
... , , SAN FRANCISCO, ... full-service direct marketing agency staffed with seasoned marketing professionals and a ... appointed Robin Raff to the position of Director of Strategy for ... Raff reports directly to ECI CEO and President Bara Oscodar. ...
... , LAKE FOREST, Ill., Aug. 31 ... in generic injectable pharmaceuticals, today announced that the U.S. Food and ... presentations of therapeutic heparin in single- and multiple-dose vials. , ... central venous catheters and for anticoagulant (blood thinning) therapy, and is ...
... , , , SCOTTSDALE, Ariz., Aug. ... failure) was in need of life flight transportation ... needed to receive the evaluation in order to get on the transplant ... due to her condition. Her health insurance company told her they would ...
Cached Medicine News:Health News:Workplace bullying is associated with sleep disturbances 2Health News:Workplace bullying is associated with sleep disturbances 3Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 2Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 3Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 3Health News:ECI Hires Robin Raff as Director of Strategy 2Health News:Hospira Receives FDA Approval for Six New Presentations of Heparin 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 3
Semi-Automated Chemistry Analyzer with model screen master. The Screen Master incorporates many powerful features in one compact unit. Useful for biochemical investigations, enzymatic, immunoturbidi...
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Unique molecular suspension in methanol for ... chromosome, and histology smears. Our special ... rapidly penetrates cellular elements producing unequaled ... detail and unexcelled brilliance in the ...
Wright-Giemsa Stain Solutions...
Medicine Products: